Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Baxalta Bails On Onconova After Phase III Study Launch

This article was originally published in Scrip

Executive Summary

Onconova Therapeutics Inc. said on March 3 that Baxalta US Inc. backed out of a deal to co-develop intravenous rigosertib three months after the companies began the Phase III INSPIRE clinical trial that will enroll 225 patients with high-risk myelodysplastic syndromes (HR-MDS).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register